drugset / Trial / NCT04066725
Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.
Timeline
- Start
- 2019-07-25
- Primary completion
- 2021-03-19
- Completion
- 2021-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | Oral |
| Subject | Aspirin | Small molecule | 325 mg | Oral |